Compare Regeneron Pharmaceuticals Inc (REGN) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while YieldMax Universe Fund of Option Income ETFs trades at $7.54. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while YieldMax Universe Fund of Option Income ETFs pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| REGN | YMAX | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $812.27 | $14.00 |
52-Week Low | $545.46 | $7.51 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
YMAX trades at $7.52 with no recent price movement. Technical indicators show a bearish trend with moving averages signaling sell and oscillators neutral. The stock faces significant resistance at $8 and support at $7. Recent news highlights concerns over shrinking dividends and layered fees in its fund-of-funds structure, impacting investor returns.
The outlook for YMAX is cautious due to declining dividend payouts and high fee structure risks. While oversold RSI levels may offer short-term bounce potential, fundamental data is unavailable, and sentiment is negative. Investors should weigh income erosion against technical oversold conditions before considering entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
